anticoagulant, prophylactic dose in COVID 19 hospitalized - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias deathsdetailed results ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021 (REV) 1.14 [0.83; 1.56]
COALIZAO ACTION, 2021 (REV) 0.64 [0.37; 1.12]
COVID-PACT, 2022 (REV) 1.10 [0.68; 1.79]
INSPIRATION, 2021 (REV) 0.92 [0.66; 1.28]
REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 (REV) 0.92 [0.72; 1.18]
0.96 [0.82 ; 1.12 ] ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021 (REV), COALIZAO ACTION, 2021 (REV), COVID-PACT, 2022 (REV), INSPIRATION, 2021 (REV), REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 (REV) 5 0% 4,882 moderate not evaluable clinical deteriorationdetailed results COALIZAO ACTION, 2021 (REV) 0.74 [0.46; 1.18]
0.74 [0.46 ; 1.18 ] COALIZAO ACTION, 2021 (REV) 1 0% 615 NA not evaluable clinical improvementdetailed results REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 (REV) 1.20 [0.97; 1.49]
1.20 [0.97 ; 1.49 ] REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 (REV) 1 0% 1,074 NA not evaluable clinical improvement (28-day)detailed results ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021 (REV) 0.79 [0.64; 0.98]
0.79 [0.64 ; 0.98 ] ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021 (REV) 1 0% 2,219 NA not evaluable death or ventilationdetailed results ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021 (REV) 1.22 [0.94; 1.59]
1.22 [0.94 ; 1.59 ] ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021 (REV) 1 0% 2,231 NA not evaluable Major thrombotic events or deathdetailed results COVID-PACT, 2022 (REV) 1.79 [1.02; 3.14]
REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 (REV) 0.96 [0.74; 1.26]
1.24 [0.68 ; 2.26 ] COVID-PACT, 2022 (REV), REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 (REV) 2 73% 1,473 moderate not evaluable Major bleedingdetailed results ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021 (REV) 0.56 [0.27; 1.13]
COALIZAO ACTION, 2021 (REV) 0.40 [0.12; 1.29]
COVID-PACT, 2022 (REV) 0.26 [0.03; 2.29]
INSPIRATION, 2021 (REV) 0.55 [0.16; 1.88]
REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 (REV) 0.68 [0.34; 1.36]
0.55 [0.36 ; 0.85 ] ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021 (REV), COALIZAO ACTION, 2021 (REV), COVID-PACT, 2022 (REV), INSPIRATION, 2021 (REV), REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 (REV) 5 0% 4,876 moderate serious Thromboembolic eventsdetailed results COALIZAO ACTION, 2021 (REV) 1.37 [0.77; 2.41]
INSPIRATION, 2021 (REV) 0.94 [0.67; 1.31]
1.05 [0.75 ; 1.48 ] COALIZAO ACTION, 2021 (REV), INSPIRATION, 2021 (REV) 2 21% 1,176 moderate not evaluable 0.2 2.0 1.0 relative treatment effect www.metaEvidence.org 2024-04-28 04:30 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 95,94,90,91
- treatments: 829
- roots T: 290
